.


Public Relations Newsroom

Where reporters connect with information.

Public Relations Newsroom Blog

HOMECID4 - Colorado Institute for Drug, Device and Diagnostic DevelopmentAquacultureFitzsimons Redevelopment AuthorityProtect DVDs & CDsColorado BioScience AssociationBioscience Colorado MagazineAccounting FirmWealth ManagementColorado CleantechCBSA Digital Media KitTargeted DonationsPR Newsroom BlogCONTACT

Monday, November 24, 2014

Well-known Life Science Executive Kevin M. Smith to Retire as President/CEO of Colorado Institute for Drug, Device and Diagnostic Development; Search Committee Formed to Hire Smith’s Successor
Kevin M. Smith to Retire as President & CEO of the Colorado Institute for Drug, Device and Diagnostic Development; Search Committee Formed to Hire Smith’s Successor

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has begun a search for a new Executive Director, as Kevin M. Smith leaves as part of a planned retirement. Mr. Smith will remain with CID4 through February 2015 to ensure a smooth and successful transition for CID4’s new leader.

Aurora, CO November 24, 2014 – Kevin M. Smith, President and CEO of the Colorado Institute for Drug, Device and Diagnostic Development (CID4) since 2010, will retire from his position as Chief Executive Officer on December 31, 2014. The announcement is made by Steve Orndorff, PhD, Chairman of the CID4 Board and President & CEO of MicroBiome Therapeutics, who says the CID4 Board has formed a search committee and that Smith will be available through February 2015 to assist in a smooth transition for the new Executive Director.

“With the ongoing changes in the healthcare and life science sectors, CID4 is revisiting how it can best support our industry,” Orndorff said. “CID4 is well positioned for its future and we believe the new Executive Director position will strengthen our alignment with the State of Colorado in our mutual quest to create new jobs and business opportunities within the dynamic life science sector of advanced industries.”

All inquiries should be directed to the ‘CID4 Search Committee’ at jobs@cid4.com. The deadline for applications is December 20, 2014. Principals only need apply, please.

About Kevin M. Smith, CID4 President/CEO

Smith was part of the team that founded CID4 in 2009. Prior to CID4, Smith was President of Gambro, Inc., the U.S. holding company for Gambro AB, the Sweden-based medical device and healthcare services company. He started his career with Arthur Young in New York and was a partner with Ernst & Young, leading the development of their Colorado life science practice at the time he left to join Gambro.

“While I will no longer be leading CID4, I will stay active in the Colorado life science community through my Board responsibilities at the Colorado BioScience Association, Donor Alliance and AlloSource, my service on the Centura Health Audit and Corporate Responsibility Committee and my investment activities at KMG Capital Partners LLC,” Smith said. “CID4’s success is grounded in the excellent technologies that are being developed in Colorado. We have invested approximately $3 million into nine early stage companies. Those firms have gone on to create 85 new jobs and raise an additional $30 million to support the commercialization of their patient-focused technologies. I am proud to have played a role in this process.” 

About the Colorado Institute for Drug, Device and Diagnostic Development

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visithttp://CID4.com.  

Contacts:

Kevin M. Smith, President/CEO CID4, http://CID4.com - kevin.smith@cid4.com, (720) 859-4047

Maggie Chamberlin Holben, APR, http://www.absolutelypr.com - maggie@absolutelypr.com, (303) 984-9801 or (303) 669-3558

Link to the PitchEngine social media release

Link to the PR.com posting
4:27 pm est 

Wednesday, October 22, 2014

CBSA Announces Finalists for 2014 ‘Company of the Year’ and ‘Rising Star’ of the Year Awards
The Colorado BioScience Association (CBSA) has chosen the finalists for the 2014 “Company of the Year” and “Rising Star” Awards, which they will present during theAnnual Awards Dinner held on Thursday, November 6, at the Marriott City Center, 1701 California Street, Denver, CO. The announcement is made by April Giles, CBSA President and CEO, who says the finalists selected are companies that have made successful achievements over the past year, showing the promise and breadth of the industry in the state. The winner of each award will be announced during the November 6th event.

Company of the Year Finalists: 

This award is designated for an established company that has announced a significant advancement within the year.

AlloSource - Centennial -http://www.allosource.org

Mountainside Medical - Boulder - http://mountainsidemed.com

Spectranetics - Colorado Springs - http://www.spectranetics.com

Rising Star of the Year Finalists: 

This award is designated for an emerging company that has announced an achievement within the year.

JustRight Surgical - Boulder -http://www.justrightsurgical.com

Silvergate Pharmaceuticals - Greenwood Village -http://www.silvergatepharma.com

Virocyt - Boulder - http://virocyt.com

In addition to Company of the Year and Rising Star, this year’s Bioscience Industry Awards also include:

* Lifetime Achievement
* Institute Leadership
* Business Partner of the Year
* Educator of the Year
* Volunteer of the Year
* Chairman’s Award

The Awards Dinner, emceed by 850 KOA Morning News Anchor Steffan Tubbs, will begin with a cocktail reception followed by dinner and a dynamic program. CBSA will first recognize those companies and individuals who are making a significant difference in Colorado’s vibrant bioscience industry. The Boettcher Foundation will then present the 2014 Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program. The event closes with a keynote address by Olympic cycling medalist and Parkinson’s survivor Davis Phinney. 

Phinney, diagnosed with Parkinson’s disease in 2000 at the age of 40, founded the Boulder-based Davis Phinney Foundation in 2004. Today, Phinney is both a role model in the cycling community and an inspiration to the estimated 1.5 million Americans and estimated 10 million worldwide who are currently living with the disease. Tens of thousands of people living with this disease have been directly touched by one of the Davis Phinney Foundation programs or through Davis Phinney’s inspirational message: “it is possible to live well with Parkinson’s today.” For more information, visit: http://www.davisphinneyfoundation.org andhttp://www.medtronicdbs.com/parkinsons/personal-stories/davis-phinney/index.htm.

Tickets for the Awards Dinner are available for purchase at the CBSA website. Individual tickets are $150. Tables (8 seats) are available for $1,250 for CBSA members and $1,500 for non-CBSA members. Please note: the Awards Dinner was a sellout event last year, so do not delay securing arrangements. Visit:http://www.cobioscience.com/events-calendar/awards-dinner-2014.

Sponsorships for the Awards Dinner are also still available. Those interested in sponsorships should contact Tracey Nilson at tnilson@cobioscience.com no later than close of business Friday, October 24. Sponsors, as of the date of this release, include: Boettcher Foundation; Cooley, LLP; Fisher Scientific, Fitzsimons Redevelopment Authority, Medtronic and Terumo BCT.

Link to the Business Wire Newswire 

Link to the PitchEngine Social Media Release
4:58 pm edt 

Wednesday, October 8, 2014

Denver Post: 'Denver-based Sapphire Technology gets funding for gemstone-tipped dental instruments'
Quoting from yesterday's posting by Laura Keeney:

"Your dental visit may soon have a lot more bling.

Denver-based Sapphire Technology LLC on Tuesday was awarded $200,000 from the Colorado Institute for Drug, Device and Diagnostic Development, or CID4, for continued development of its dental instruments made with sapphires.

Sapphire, which is a gemstone variety of corundum, ranks at the top of the Mohs scale of mineral hardness — the universal standard to measure the hardness of gemstones and minerals.

The gemstone has been in the news recently amid speculation that Apple might use highly scratch-resistant glass made of sapphires for its new iPhone screens.

But what does this have to do with dental work?"
 
Link to the Denver Post
5:50 pm edt 

Tuesday, September 16, 2014

Colorado Med Device Company dBMEDx Wins the Venture Showcase Competition at BioWest 2014
dBMEDx (Littleton)won the 2014 Venture Showcase competition at the BioWest Conference and Expo yesterday at the Marriott City Center Denver, receiving the $7,500 cash prize. The announcement is made by April Giles, Colorado BioScience Association (CBSA) President and CEO who says, “We are very proud to announce dBMEDx as the winner of the Venture Showcase. The check presentation was an exciting end to the BioWest Conference. The award not only includes the cash prize of $7,500 but also includes recognition and exposure for the company. ” This award is sponsored by Dorsey and Whitney LLP and The Metro Denver Economic Development Corporation. BioWest, the Rocky Mountain Region's premier medical device and biotechnology conference, is organized by the CBSA and held every other year. 

dBMEDx is a Colorado-based medical device development company that is creating clinical decision and patient monitoring devices using its patented, non-invasive scanning technology. These devices combine the power and safety of ultrasound with sophisticated image processing electronics and software to provide simple, fully automated and completely noninvasive diagnostic measurements.  Fully automated means that very little training is required and the user does not need any experience with ultrasound to use our devices. To enable this level of automation, dBMEDx has successfully created and patented an extremely compact, wireless, 3D scan engine.

The scan engine, which can be held in the palm of the hand, includes a complete 3D ultrasound imaging machine and automated image processor within a small, sealed tube.  The system also includes an integrated Bluetooth radio and rechargeable battery, which is inductively charged. The company is in the process of commercializing the first application for this technology, the BBS Revolution™ device for automated bladder volume measurement, and has a range of pipeline of products for other clinical applications as well. Visit: http://www.dbmedx.com.

Video of winning Venture Showcase pitch by dBMEDx CEO David Shine:

 
http://youtu.be/TUoQK71wPEU 

The Venture Showcase format allowed each company’s lead executive to make a 15-minute presentation with an accompanying slide deck explaining their technology and business plan to a panel of judges in front of a live audience. This year's judging panel included the following:

• Michael Weiner, Partner, Dorsey
• Ned Scheetz, Managing Director, Aphelion Capital
• Steve VanNurden, President and CEO, Fitzsimons Redevelopment Authority

The three 2014 Venture Showcase finalists included:

dBMEDx – Littleton http://www.dbmedx.com
KromaTiD, Inc. - Fort Collinshttp://www.kromatid.com
Mighty Oak Medical – Englewoodhttp://www.mightyoakmedical.com

The BioWest Conference was attended by more than 300 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. “We look forward to the continued growth of the bioscience industry and presenting the conference in again 2016,” Giles concludes.

Link to the related Business Wire

Link to the PitchEngine Social Media Release 
2:26 pm edt 

Monday, July 7, 2014

New Issue: Bioscience Colorado Magazine 2014-15 Article Overview

2014BioscienceColorado.jpg

 

Make sure to check out these "great reads" -- and save the new directory for future use.

The complete flip book of the issue can be found online at:http://www.cobioscience.com/magazine2014flip-book/

Articles - Direct Links:

Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 
  
Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 
  
Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 
  
Colorado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 
  
U.S. Hub: Colorado Is Where Drug, Device and Therapy Intersect 
  
Boettcher Investigators: Webb-Waring Biomedical Research Program 
  
Found in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 
  
Tech Transfer Offices Connect the Dots between Research and the Marketplace, Stimulate State’s Economy 
  
Colorado Bioscience Industry by the Numbers: Financing and Acquisitions 
  
Colorado Bioscience Grant Programs: Innovation Engines 
  
Colorado Bioscience Industry Directory – updated company information – great to keep on file 

Bioscience Colorado magazine is an integral part of the Association’s mission to support the Colorado bioscience community through advocacy, resources and advancement of opportunities for collaboration. It reaches thousands of bioscience, economic development, legislative, university and industry leaders. Colorado’s bioscience assets are also valuable. Device, diagnostic and therapeutic products created here have a significant economic impact—27,000 in total workforce— translating to over $10 billion in the State’s economy each year. In addition, over 60 acquisitions, financings and grants, totaling over $4 billion, were reported within the 2013 calendar year, further developing the industry’s ecosystem. 

Download the new magazine pdf at: http://www.cobioscience.com/Magazine%202014/CBSA_magazine_061314-lowres.pdf

3:09 pm edt 

Wednesday, November 20, 2013

CBSA Commends the State of Colorado For Granting $3.135 Million To Advance Bioscience Research from Bench to Marketplace
OEDIT.gif
 
Colorado BioScience Association (CBSA) commends the Colorado Office of Economic Development and International Trade (OEDIT) for awarding $3.135 Million in Commercialization Infrastructure grants under the Bioscience Discovery Evaluation Grant Program (BDEGP) last week. April Giles, CBSA President and CEO, says "CBSA appreciates the OEDIT for its ongoing commitment to the state’s bioscience industry through the Bioscience Discovery Evaluation Grant Program, which was created in 2006 by the Colorado General Assembly. These key commercialization infrastructure grants funded last week are critical to advancing bioscience research from the bench into the marketplace."
 
Commercial Infrastructure grantees announced by the OEDIT include:

The Colorado Institute for Drug, Device and Diagnostic Development (CID4): $1,350,000 
CID4 is managing life science discoveries from Colorado research institutions and Colorado start-ups and early-stage businesses with the goal of creating bioscience jobs in Colorado. Grant funds support operations and the development and management of life-science discoveries. The CID4 has seven early-stage companies under its guidance supporting their operational development and attracting additional investment to meet their needs. Visit: http://cid4.com

Colorado Center for Drug Discovery (C2D2): $750,000 
Based at Colorado State University, C2D2 is a resource to faculty at Colorado research universities, bringing biology and chemistry faculty together to use chemical libraries, computational resources, bioinformatics, cheminformatics, database support, virtual high throughput screening, and Computer Aided Drug Design to pharmacologically validate drug candidates with patent-protected chemical matter and innovative therapeutics for unmet medical needs. C2D2 supports several inter-institutional projects with funding and resources. Further, C2D2 offers compounds to investigators through its screening library and medicinal chemistry services that are critical in the drug discovery process. Visit: http://c2d2.org

The Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado: $410,248 
The University of Colorado Skagg's School of Pharmacy at Anschutz developed an HTS/HCS (high throughput/content screening) Core Facility for drug discovery. This resource has been utilized by more than 100 researchers and companies advancing the science and helping to secure intellectual property.http://www.ucdenver.edu/academics/colleges/pharmacy/Pages/SchoolofPharmacy.aspx

The BioFrontiers Institute at the University of Colorado: $624,752
The BioFrontiers Institute is a state-of-the art research and education facility that links the basic sciences, engineering, clinical practice, and industry at the University of Colorado's Boulder campus to support breakthrough developments in areas such as engineering human tissues, RNA enzyme and aptamer-based pharmaceutical, biorefining, and genetics. Grant funds support equipment, resources and personnel costs to develop the core facilities of the institute. With grant support, the institute has developed one of the largest repositories of shRNAs in the world at the Functional Genomics Facility. Colorado companies partner with the institute to improve their products. Ventria, a Fort Collins based pharma-biologics company, has used mass spectrometry services to detect oxidation in recombinant protein samples manufactures for human terapeutics. OPX Biotechnologies based in Boulder utilizes mass spectrometry to detect levels of intracellular metabolytes in biofuel molecule samples. Longmont-based Avery Brewing Co. has partnered with the Next-Generation DNA Sequencing Facility to develop an early-detection test for yeast cross-contamination to reduce waste and inefficiencies in their production process. Visit: http://biofrontiers.colorado.edu
 
Link to the PitchEngine social media news release
10:41 pm est 

Wednesday, October 16, 2013

The Colorado BioScience Association Celebrates Ten Years At November 7th Event

10thAnnualAwards.jpg

 

Colorado BioScience Association (CBSA) will be celebrating its 10th anniversary at the Annual Awards Dinner, Thursday, November 7, 2013, 5:30 to 9:00 pm, at the Denver Marriott City Center. The announcement is made by April Giles, President and CEO of the Colorado BioScience Association (CBSA) who says, “Over the past 10 years the Association has grown from a small startup enterprise to a mature and successful organization. This is our night to celebrate and honor our community.”

Three key leaders who have made significant contributions to the industry and community in Colorado will be sharing their memories, insight and vision.

Larry Gold, Ph.D., Founder and CEO, SomaLogic, and Professor at the University of Colorado Boulder
Chris Christoffersen, Ph.D., General Partner, Lightstone Ventures & Partner, Morgenthaler Ventures
David Perez, President and Chief Executive Officer, Terumo BCT, Chairman, Blood Management Business Division, Terumo Corporation

This year’s event will feature three very special honors given only for the 10th anniversary, including the Pioneering Award, Founders Award and Visionary Award. The awardees will be announced on stage by emcee Steffan Tubbs, Morning Co-Host on 850 KOA News.

* The Pioneering Award will be given to individuals who have led the bioscience industry in Colorado from the ground up. These leaders have made significant contributions to the industry and the community as a whole.

* The Founders Award will be given to organizations that have shaped CBSA over the past 10 years. Through their leadership and support CBSA has been able to succeed and serve the industry.

* The Visionary Award will be given to one bioscience leader who looks ahead and continues to build the bioscience industry in the future.

The evening will also honor the 2013 Class of Boettcher Investigators of the Webb-Waring Biomedical Research Program, plus the outstanding annual company and individual awards.

Link to the Business Wire release

Link to the PitchEngine Social Media newswire

1:36 pm edt 

Wednesday, September 4, 2013

Leading CEOs Keynote 2013 Rocky Mountain Life Science Investor and Partnering Conference in Denver

RMLIPCJJClovisArray300.jpg

 

The 2013 Rocky Mountain Life Science Investor and Partnering Conference keynote breakfast will include Kyle Lefkoff, founder and General Partner of Boulder Ventures, leading a conversation with the CEOs of Colorado's two premier publicly-traded pharmaceutical companies – Patrick Mahaffy, Founder and CEO of Clovis Oncology and Ron Squarer, CEO of Array BioPharma. The announcement is made by April Giles, President and CEO of the Colorado BioScience Association (CBSA) who says the regional conference will also feature a keynote luncheon presentation by Jeff Calcagno, M.D., Principal, Venture Investments, Johnson and Johnson Development Corporation.

Lefkoff, one of the region’s leading venture capitalists and a member of the conference steering committee since 2009, says: “Clovis Oncology and Array BioPharma have been incredibly successful reaching both funding and developmental milestones. This is a great opportunity to hear first-hand from their leadership how they have achieved this success and what they look forward to in the future.”
 
Link to the Business Wire release
 
Link to the PitchEngine Social Media Release

2:44 pm edt 

Friday, August 23, 2013

Viewpoint: 'Building more investors is vital to the Colorado economy'
DBJLOGO.jpgQuoting from today's posting in the Denver Business Journal:

"Since January 2011, we’ve created 97,000 jobs and now have 2.4 million jobs in the state — prerecession levels. And we have the fourth-fastest job growth in the nation. We are continuing to successfully woo a number of industries and we’re enhancing our advanced industries with a 10-year, $150 million investment.

We are just missing one key piece of the economic pie: investors. Venture-capital investment is critical to the growth of successful startup companies...

...We’re working on creating more funding opportunities. OEDIT, in partnership with the Colorado BioScience Association and Johnson & Johnson Development Corp., established the Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC) in 2009. Celebrating the third biennial conference on Sept. 19, RMLIPC will bring together more than 50 investors to Denver to showcase 30 regional startup companies in the biotech, diagnostic, medical device and pharmaceutical industries. The Rockies Venture Club, along with the Impact Angel Group, are working their connections with local angel investors and entrepreneurs." 

Link to the OpEd piece authored by Ken Lund 
3:22 pm edt 

Rocky Mountain Life Science Investor and Partnering Conference Announces Thirty Regional Companies for 2013 Presentation Lineup

RMLIPC2013logo.jpg

 

Denver, CO, August 12, 2013 – Thirty companies from Arizona, Colorado, Montana and Utah have been chosen to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC), September 18-19, at The Ritz-Carlton in Denver, Colorado. The announcement is made by April Giles, President & CEO of the Colorado BioScience Association (CBSA), on behalf of the RMLIPC Selection Committee, who says the presenting companies were selected from more than 60 applicants by a committee of investors and industry experts. 
2013 Rocky Mountain Life Science Investor and Partnering Conference Presenting Companies:

AmideBio, LLC - Boulder, CO - http://www.amidebio.com 
Biodesix - Boulder, CO - http://www.biodesix.com
BioFusionary - Wheat Ridge, CO - http://biofusionary.com
Boulder Diagnostics - Boulder, CO - http://www.boulderdiagnostics.com 
Convoy Therapeutics - Oro Valley, AZ - http://www.convoytx.com 
DiscGenics - Salt Lake City, UT - http://discgenics.com 
EndoShape - Boulder, CO - http://endoshape.com 
ENDURX Pharmaceuticals, Inc. - Oro Valley, AZ - http://www.endurxpharma.com 
FitBionic - Boulder, CO - http://www.fitbionic.com 
Lazarus Medical Technologies - Salt Lake City, UT -http://www.lazarusmedtech.com 
Lineagen - Salt Lake City, UT - http://www.lineagen.com 
MBio Diagnostics - Boulder, CO - http://mbiodx.com 
MSDx - Tucson, AZ - http://www.msdx.co 
Nasseo, Inc. - Peoria, AZ - http://www.nasseo.com 
Neuro Assessment Systems - Littleton, CO - http://www.neuroassessments.com 
Prima-Temp, Inc. - Boulder, CO - http://prima-temp.com 
Regenesis Biomedical - Scottsdale, AZ - http://www.regenesisbio.com 
Renaptys Vaccines, LLC - Aurora, CO - http://www.renaptys.com 
Rocky Mountain Biologicals - Missoula, MT - http://rmbio.com 
Sharklet Technologies, Inc. - Aurora, CO - http://sharklet.com 
Sinopsys Surgical - Boulder, CO  - http://www.sinopsyssurgical.com 
Surefire Medical - Westminster, CO - http://surefiremedical.com 
SuviCa - Boulder, CO - http://suvica.com 
Transverse Medical - Evergreen, CO - http://www.transversemedical.com 
Ventria Bioscience - Fort Collins, CO - http://ventria.com 
VetDC Inc. - Fort Collins, CO - http://www.vet-dc.com 
Vivaldi Biosciences - Fort Collins, CO - http://www.vivaldibiosciences.com 
Wasatch - Salt Lake City, UT - http://www.microfl.com 
Xalud Therapeutics, Inc. Boulder, CO - http://www.xaludthera.com
Xenograft Corporation - Missoula, MT - http://www.ihimontanafoundation.org

The 2013 Rocky Mountain Life Science Investor and Partnering Conference – spearheaded by the Colorado BioScience Association in collaboration with associations in Arizona, Montana, New Mexico and Utah — will open with a reception at the Colorado Governor’s Mansion September 18th and follow with a full day of company pitch presentations September 19th. The keynote breakfast will include Kyle Lefkoff, founder and General Partner of Boulder Ventures, leading a conversation with the CEOs of Colorado's two premier publicly-traded pharmaceutical companies-Patrick Mahaffy, Founder and CEO of Clovis Oncology and Ron Squarer, CEO of Array BioPharma. The keynote lunch will be a presentation from Johnson and Johnson Development Corporation executive leadership. For more information and registration details, visit http://www.RockyMtnBioInvest.com 

On Twitter, please use the hashtag #RockyMtnBioInvest for your tweets.

Link to the PitchEngine social media release

3:19 pm edt 

Sunday, August 18, 2013

SeafoodSource: Bell Aquaculture's 'McCowan honored for aquaculture work'
SeafoodSourceLogo.jpg
 
Quoting from the August 16th posting:

"The president of an Indiana-based aquaculture company has been honored with an award for work in his field.

Norman McCowan, the president of Bell Aquaculture, received the Agrivision Award this week, recognizing him as a leader of the agricultural community in Indiana."
 
Link to SeafoodSource.com
12:15 pm edt 

Wednesday, July 24, 2013

CBSA Commends Boettcher Foundation For Ongoing Commitment To Early-Career Investigators Through Its Webb-Waring Biomedical Research Program
Boettcher.jpg

The Boettcher Foundation Board of Trustees have released the names of the eight early-career scientists selected for the fourth class of Boettcher Investigators in the Webb-Waring Biomedical Research Program. The announcement is made by April Giles, President and CEO of the Colorado BioScience Association (CBSA), who said "Our association commends Boettcher Foundation for its ongoing commitment to this stellar program that assists early-career investigators in our state to continue their important research."

Launched in 2010, the Webb-Waring Biomedical Biomedical Research program fills an unmet need in the state by assisting early-career investigators engaged in biomedical sciences to advance their research. Further, the program honors the tradition of Colorado's Webb and Waring families by investing in science that has the possibility of making significant contributions to human health. Boettcher Foundation is a Titanium Sponsor of the CBSA.

The 2013 (fourth) Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program includes:

* Dr. Amrut V. Ambardekar, M.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Medicine - Cardiology, Myocardial Recovery After Ventricular Assist Device Implantation

* Dr. Joseph A. Brzezinski, Ph.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Ophthalmology, Mechanisms of Retinal Development and Disease

* Dr. Soyeon Park, Ph.D., University of Colorado Boulder, Assistant Professor of Molecular, Cellular and Developmental Biology, Molecular Mechanisms of Proteasome Biogenesis

* Dr. Abigail L. Person, Ph.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Physiology and Biophysics, Corollary Discharge Pathways Underlying Schizophrenia Symptoms

* Dr. Michael Strong, Ph.D., National Jewish Health, Assistant Professor of Genes, Environment, and Health, Genomics of Respiratory Disease Associated Pathogens

* Dr. Lucas Argueso, Ph.D., Colorado State University, Assistant Professor of Radiation and Cancer Biology, Gene Copy Number Variation

* Dr. Brad Borlee, Ph.D., Colorado State University, Assistant Professor of Bacteriology, Molecular Regulation of Bacterial Pathogenesis

* Dr. Melissa Krebs, Ph.D., Colorado School of Mines, Assistant Professor of Chemical & Biological Engineering, Controlled Delivery of Therapeutics from Biopolymer Systems

With the addition of the 2013 Class, there are now 22 Boettcher Investigators conducting research in the following Colorado institutions: University of Colorado Anschutz Medical Campus, University of Colorado Boulder, Colorado State University, National Jewish Health and Colorado School of Mines. All grant awards are $225,000.
 
Link to the Business Wire newswire

Link to the PitchEngine Social Media Release
5:19 pm edt 

Thursday, December 13, 2012

CBSA 2012 Awards: Best Of Colorado's Bioscience Industry

CelebrationLogo.jpgRecipients of 2012 CBSA Awards include:


Educator of the Year - Shawndra Fordham, Biotech Teacher, Rock Canyon High School (Highlands Ranch) Shawndra Fordham’s enthusiasm and dedication to education has created one of the best programs in the state and has made an impact on her students and the industry. She has helped secure thousands of dollars in grant funding from federal institutions, foundations and industry and has created a program that challenges college curriculums around the country and her students have gone on to STEM focused majors and careers. Visit: http://go.dcsdk12.org/rchs

Volunteer of the Year - Mark Spiecker, CEO, Sharklet Technologies (Aurora) Mark Spiecker is the Education Chair of the CBSA Board of Directors and a founding Board member of the new Colorado Bioscience Institute. He has been integral in developing key strategic efforts and partnerships with the Colorado education community. Visit: http://www.sharklet.com/about-us/management

Volunteer of the Year - Nicole Garneau, Ph.D., Curator and Chair of the Health Sciences Department, Denver Museum of Nature and Science (Denver) Dr. Garneau is Co-Chair of the CBSA Education Committee and a founding Board member of the new Colorado Bioscience Institute. She has been instrumental in developing strategy and implementing the successful internship program. Visit: http://www.dmns.org/nicole

Business Partner of the Year – Rockies Venture Club (Denver) Rockies Venture Club (RVC) has successfully partnered with CBSA to support Colorado’s bioscience industry. RVC has added active angel groups, sophisticated training and education, and events to assist early stage company funding. Visit: http://www.rockiesventureclub.org

Business Partner of the Year – Dorsey and Whitney LLP (Denver) Dorsey and Whitney has been a long standing supporting partner for Colorado’s bioscience industry; supporting the annual conference and the BioBoot Camp program. This year they dedicated countless hours of pro bono and consulting services to establish the new Colorado Bioscience Institute. Visit: http://www.dorsey.com

Rising Star of the Year - Sophono (Boulder) Sophono manufactures implanted magnetic hearing devices. This year the company has secured $7 million in new growth capital financing to fuel product and business development efforts. They have tripled their square footage to expand their manufacturing facilities in Boulder. Visit: http://sophono.com

2012 'Rising Star of the Year' Finalists included: InDevR, Inc., Boulder (http://www.indevr.com); Mosaic Biosciences, Aurora and Boulder (http://www.mosaicbio.com); and Surefire Medical, Inc., Westminster (http://www.surefiremedical.com).

Company of the Year - TOLMAR (Fort Collins) TOLMAR is a pharmaceutical research, development, manufacturing, and commercial operations company that has seen tremendous growth this past year. The pharmaceutical company announced their expansion into a 146,000-square-foot building in Windsor. TOLMAR is continually engaged in community efforts for the industry and partnered with CBSA this summer to launch the internship program. Visit: http://www.tolmar.com

2012 'Company of the Year' Finalists included: Bal Seal Engineering, Inc., Colorado Springs (http://www.balseal.com) and Covidien (Colorado operations), Boulder (http://www.covidien.com).

Chairman’s Award - Sheridan Ross (Denver) Sheridan Ross played a significant role in the coordination and application efforts to bring a U.S. Patent and Trademark Office to Denver. John Posthumus, Partner and Patent Attorney at Sheridan Ross worked with local, state and federal legislators along with business and economic development leaders for many years to accomplish this major development in the Colorado economy that will impact the bioscience industry in the years to come. Visit: http://www.sheridanross.com

Lifetime Achievement Award - William Freytag, Ph.D., Former Chairman and CEO, Myogen (Boulder) Dr. Freytag’s 25 years of experience in the biotechnology and pharmaceutical industries include serving as Chairman and CEO of Myogen Inc. plus other senior executive and research positions. He currently serves on multiple boards including the BioFrontiers Institute, Board of Trustees of the University of Colorado Foundation, and the Fitzsimmons Redevelopment Authority. Visit: http://leeds.colorado.edu/board/freytag

CBSA also announced the new Colorado BioScience Institute to its community at the Annual Awards Dinner Celebration December 6th with this video overview: http://youtu.be/2qgVEgNTlwI -- video by Robin Bond Media: http://robinbondmedia.com

Link to view all the video highlights of the celebration: http://coloradobio.blogspot.com/2012/12/video-highlights-colorado-bioscience.html

Link to the BusinessWire

Link to the PitchEngine Social Media News Release
6:46 pm est 

Wednesday, July 11, 2012

9News Denver: 'Colo. bioscience industry, patients to benefit from new law'
HolliRiebel9News.jpg
CBSA Pres/CEO Holli Riebel
interviewed with 9News yesterday regarding the new federal law that cuts the FDA's approval timetable for new drugs. Quoting from the 9News posting:

"Supporters say the bill would benefit hundreds of Colorado startups that are developing novel medicines and therapies. They say the provision could also help severely ill patients who are willing to take experimental drugs that haven't undergone the full battery of tests for all possible side effects and complications...

...About 600 bioscience companies, research institutions and venture capital groups in Colorado employ about 20,000 people, and the industry continues to grow despite the sluggish economy, according to the Colorado Bioscience Association."

Link to the video report
or view here: http://www.9news.com/rss/story.aspx?storyid=277012
12:46 pm edt 

Friday, June 15, 2012

CBSA Releases 2012 Edition of Bioscience Colorado Magazine - Colorado Centers of Excellence: Elevated Thinking
2012MagazineCover.jpg
The 2012 issue of Bioscience Colorado highlights centers of excellence within the state, including Cancer, Infectious Disease, Respiratory, Cardiac and Biofuels. The research the writers and experts have compiled for this issue illustrates that there are several components—infrastructure, expertise, industry connections, and patient outcomes. Each article focuses on a center and examines the elements that make it truly excellent.

The new issue also includes:

* Complete listing of every bioscience company in the state

* Annual industry financing and investment overview

* Bioscience Discovery Evaluation Grant Program (BDEGP) update

This publication is an integral part of the Association’s mission to support the Colorado bioscience community through advocacy, resources and advancement of opportunities for collaboration. It reaches thousands of bioscience, economic development, legislative, university and industry leaders.

The new magazine rolls out the industry’s new branding campaign for Bioscience in Colorado: Elevated Thinking. We have some of the top research institutions in the country and over 600 bioscience companies led by the best in the industry—creating the vision and drive to succeed. That’s why so many great ideas that impact the globe start and grow here in Colorado.

Link to the magazine pdf

Link to the Business Wire release

Link to the PitchEngine Social Media newswire
6:02 pm edt 

Sunday, June 3, 2012

Bell Aquaculture launches OMRI Listed Fish Rich™ 2-2-2 Organic & Fish Rich+ 6-3-3 Fertilizers
FishRichOMRI.jpg
Bell Aquaculture, the nation's largest yellow perch (Perca flavescens) farm and pioneer in sustainable fish farming operations, is formally launched its new OMRI Listed 'Fish Rich Organic 2-2-2 Fertilizer' and 'Fish Rich+ 6-3-3 Fertilizer' products at the 2012 National Hardware Show in Las Vegas in May.

The announcement is made by Norman McCowan, president of Bell Aquaculture, who says, "Fish have been used as soil fertilizer since the Native Americans first began farming our nearby land centuries ago. Our natural plant fertilizers, marketed as the Fish Rich brand, are made from the remains of the Bell Perch processed at our aquaculture facility in Indiana."

Fish Rich 2-2-2 (Organic) - Fish Rich is OMRI Listed and is allowed for use in organic crop production under the USDA National Organic Program rules. It is completely garden and human safe.

Fish Rich+ 6-3-3 - Fish Rich+ is a natural based fertilizer, just “plussed up” with some nitrogen and potassium. This formula will offer your plants faster greening, swifter root establishment and more brilliant, longer lasting blooms.

Both products are available for purchase online at the company website: http://www.bellaquaculture.com

Link to the PR Web newswire

Link to the PitchEngine Social Media Release
3:23 pm edt 

Thursday, March 15, 2012

Mayo Clinic exec to lead Fitzsimons Redevelopment Authority (via Denver Business Journal)

SVN.jpg
Aurora, CO, March 14, 2012 - Following an extensive national search, Fitzsimons Redevelopment Authority (FRA) has named Steve VanNurden as its new President and Chief Executive Officer, beginning in late May. The announcement is made by John M. Shaw, Chair of the FRA Board of Directors, who said: "Steve, a seasoned leader in the life science/bioscience space, comes to us from Mayo Clinic in Rochester, Minnesota."

The appointment of Mr. VanNurden is further evidence of the FRA's continued commitment to support the development of life science companies in Colorado in partnership with the State’s research institutions. He will be working with universities, local economic development agencies, state and local governments, and the bioscience industry to promote the successful development of the 180 acre Colorado Science + Technology Park, which is adjacent to the University of Colorado’s Anschutz Medical Campus in Aurora.

Steve Hogan, Mayor of the City of Aurora and FRA Board member stated, “Steve is the partner we need to fulfill the promise of the bioscience industry park. His working relationships span nationally and internationally, which will be a great advantage for us.”

Steve VanNurden is currently Chair of Mayo Clinic Ventures, the invention arm for Mayo Clinic. Under Mr. VanNurden’s direction, this division is responsible for patenting and commercializing Mayo’s discoveries, inventions and other intellectual property. Since 1986, Mayo Clinic Ventures has successfully commercialized over 2,000 technologies and has been granted more than 1,200 patents. Under the guidance of Mr. VanNurden, Mayo’s technology based ventures efforts have paid off, resulting in the formation of 45+ Mayo Clinic start-up companies.

Link to the PitchEngine Social Media Release
Link to the PR Newswire Release

3:05 pm edt 

Monday, February 20, 2012

Bell Aquaculture & Indiana Soybean Alliance Jointly Announce 'Future of Fish' Partners
ISALogo.jpg
Albany & Indianapolis, IN [released 1/25/12] - Bell Aquaculture, a pioneer in sustainable fish farming operations, teamed with Indiana Soybean Alliance, Virginia Cobia Farms, University of Wisconsin-Milwaukee's School of Freshwater Sciences and The Conservation Fund's Freshwater Institute to present the 'Future of Fish' at Bell Aquaculture's operations in Albany and Redkey, Indiana. The announcement is made jointly by Norman McCowan, President of Bell Aquaculture, and Shelia Lingle, Director of Aquaculture for Indiana Soybean Alliance.

According to McCowan: "We are simply thrilled to be partnering with the Indiana Soybean Alliance, Virginia Cobia Farms and The Conservation Fund's Freshwater Institute to advance the knowledge of best practices in the Aquaculture Industry in the U.S. Our first event was January 11th here in Redkey and Albany. We look forward to hosting similar events in the near future."

Further, says Lingle: "As our country, and world, seeks sustainable, quality food options, Indiana Soybean Alliance is very pleased to be supporting this effort to provide healthy, great-tasting and ecologically responsible fish options for consumers. We've been working closely with Bell Aquaculture since its inception in 2005 to develop more sustainable, soy-based feed options for the aquaculture industry."

The 'Future of Fish' on January 11th included tours of Bell Aquaculture's production and processing facilities, followed by luncheon presentations from Fred Binkowski, Senior Scientist, School of Freshwater Sciences University of Wisconsin-Milwaukee; Steven T. Summerfelt, Ph.D, P.E., Director of Aquaculture Systems Research, The Conservation Fund's Freshwater Institute; Dr. Espen Staubo, President & CEO of Low Salinity, Inc., and Virginia Cobia Farms; and Steve Hart, Ph.D., Executive Director of the Soy Aquaculture Alliance.

The luncheon was prepared by chefs from The Chef’s Academy, Indianapolis. Entrees featured breaded Bell Perch and Virginia Farms Cobia and Pompano.

Link to the PR Web Newswire
3:17 pm est 

Denver's Absolutely PR Provides Yearend Review of 2011 Client Milestones & Key Media Placements
20112012photo.jpg
Lakewood, CO [released 12/31/11] - Metro Denver-based Absolutely Public Relations celebrated its 12th calendar year in business in 2011 and achieved key media placement results for clients in both the traditional and social media spaces. This yearend review is shared by Absolutely PR Owner/Founder Maggie Chamberlin Holben, APR, who says, "Absolutely PR assisted Bell Aquaculture (including its new Fish Rich™ fertilizer product line); Cabela's; Cat Care Society (CCS); Colorado BioScience Association (CBSA), Colorado Institute for Drug, Device and Diagnostic Development (CID4); Fitzsimons Redevelopment Authority; Joseph Decuis Gourmet Restaurant, Farm, Emporium, Culinarium and Inn; Medivance, Inc.; Dr. Martha Lucas/Cosmetic Acupuncture Seminars; and Holben Building Corporation in 2011." 

Absolutely PR offers PublicRelationsNewsroom.com, Expert411.com and DenverPRNewsroom.com to help clients achieve media relations success. The company also maintains News Feed Blogs to turn up the volume on client messaging in the social media blog space.

Link to the PR Web newswire

3:15 pm est 

Fitzsimons Redevelopment Authority Announces Second Phase of Strategic Refocus With $8 Million Expansion to Bioscience Park Center
elevations.jpg
Aurora, CO [released 12/12/11] - In furtherance of its renewed commitment to support the growth of early-stage Colorado bioscience companies, especially those developing technologies from Colorado's research institutions, Fitzsimons Redevelopment Authority (FRA) is expanding its Bioscience Park Center building (BPC) with an $8 million, 37,000-square-foot accelerator facility, increasing the BPC in excess of 50 percent. The announcement is made by Denise Brown, FRA Interim Executive Director, who says, "The new accelerator space will be leased to companies in the modest growth stage. We have a number of companies in the BPC incubator ready to make this advancement in addition to interest from other companies, both in-state and out-of-state, as well."

The FRA Board of Directors has been working with FRA staff, FRA's real estate development partner Forest City Science + Technology Group, consultants and lenders for the past several months to finalize this expansion. Based on the team's recommendation, the three-story accelerator will be built to the west of the current building with a new parking lot located to the north of BPC. Ground broke in October and construction has been progressing since, with completion expected by June, as recently reported in the Aurora Sentinel, http://www.aurorasentinel.com/email_push/news/article_95c4538e-1792-11e1-a67e-001cc4c03286.html.

Link to the PR Web newswire


Link to the PitchEngine Social Media Release
 
3:11 pm est 

Thursday, December 29, 2011

Colorado BioScience Association Celebrates 2011 Industry Standouts
PhotoForBlog.jpg
The Colorado BioScience Association (CBSA) honored the outstanding bioscience companies and individuals in the state during its 9th Annual Awards Dinner at the Downtown Denver Embassy Suites. The CBSA's Annual Awards program showcases the significant achievements in the state's bioscience industry throughout the year.

Recipients of 2011 awards include:

Lifetime Achievement Award - Brian, Greg and Jeff Baldwin
Brian Baldwin founded Baxa Corporation in 1975 and grew the company steadily over the succeeding 36 years along with the leadership of sons Greg and Jeff. Creating technology that saves patient lives, Baxa Corporation provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Visit: http://www.baxa.com

Company of the Year - LABS Inc.
LABS, Inc. has grown to service clients across many healthcare industries over the past 30 years. Recently, they added a Cell and Molecular Biology Department to their already growing business. Labs Inc. has been the market leader in laboratory testing for Infectious Disease, Microbiology, and Immunogenetics. Visit: http://www.labs-inc.org

Rising Star of the Year - Ventria Bioscience
Ventria Bioscience is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. Ventria’s technology platform ExpressTec is a safe, affordable and sustainable manufacturing technology that achieves recombinant protein yield that is many times higher than alternative systems. Visit: http://www.ventria.com

Volunteer of the Year - Timothy Rodell, M.D. President and CEO, GlobeImmune
Timothy Rodell’s leadership and community involvement has greatly contributed to Colorado’s bioscience industry. He contributed significantly to Senator Bennet’s Colorado Competes Report as a member of the Innovation Roundtable. He also has been a voice at the federal level with a seat on BIO’s national Board leading our industry forward. Visit: http://www.globeimmune.com

Educator of the Year - Melissa Reynolds, Ph.D., Assistant Professor of Chemistry, Colorado State University
Melissa Reynolds Ph.D. joined the Colorado State University faculty in 2009 as an Assistant Professor of Chemistry and is a participating faculty member in the School of Biomedical Engineering. In addition to teaching graduate and undergraduate courses she has organized professional development and entrepreneurship programs and mentored over 25 multidisciplinary students. Her positive leadership and encouragement has been continually evident to her colleagues, funders and the bioscience community as a whole. More about Dr. Reynolds: http://www.news.colostate.edu/Release/5620

Business Partner of the Year - Ernst & Young
Ernst & Young has been a strong partner for over seven years helping to move Colorado’s bioscience industry forward. They have provided excellent service to the industry with expertise and dedication to our companies. Visit: http://www.ey.com

Legislator of the Year - State Representative Cheri Gerou
Representative Cheri Gerou has shown continued support for the bioscience community. She was involved in introducing and enabled the passage of HB 1283 and SB 47 to extend and further fund the Bioscience Discovery Evaluation Grant Program. Visit: http://cherigerou.com

Chairman’s Award - Johnson & Johnson
Johnson & Johnson’s dedication to advocacy and strategic development as an industry leader has advanced bioscience in Colorado. The company has continually supported CBSA’s efforts to advance the regional bioscience community including the development of CBSA’s Rocky Mountain Life Science Investor Conference and presence on the Board of Directors. Visit: http://www.jnj.com

Chairman’s Award - U.S. Senator Michael Bennet
Senator Michael Bennet has championed Colorado’s bioscience issues at the Capitol on several major issues including spearheading the Colorado Innovation Economy Committee and the “Colorado Competes” report, of which CBSA co-chaired; a CEO roundtable event with FDA Commissioner Hamburg; and The Medical Device Regulatory Improvement Act, introduced to boost Medical Device innovation and FDA reform. Senator Bennet leadership and perseverance continue to benefit the bioscience community as a whole. Visit: http://bennet.senate.gov

Link to the Business Wire newswire
12:54 pm est 

2014.11.01 | 2014.10.01 | 2014.09.01 | 2014.07.01 | 2013.11.01 | 2013.10.01 | 2013.09.01 | 2013.08.01 | 2013.07.01 | 2012.12.01 | 2012.07.01 | 2012.06.01 | 2012.03.01 | 2012.02.01 | 2011.12.01 | 2011.11.01 | 2011.10.01 | 2011.09.01 | 2011.06.01 | 2011.01.01 | 2010.08.01 | 2010.07.01 | 2010.05.01

Link to web log's RSS file